TY - JOUR
T1 - Accelerated Partial Breast Irradiation
T2 - Florence Phase 3 Trial Experience and Future Perspectives
AU - Meattini, Icro
AU - Kim, Kyubo
AU - Livi, Lorenzo
N1 - Funding Information:
I.M.: reports as occasional speaker honoraria supported by Eli Lilly, Novartis, Pfizer, Accuray, and Seagen, outside the submitted work. The remaining authors declare no conflicts of interest.
Publisher Copyright:
© 2023 Authors. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Accelerated partial breast irradiation Florence phase 3 trial is a single-center study comparing intensity-modulated based accelerated partial breast irradiation (PBI, 30 Gy in 5 fractions) and whole breast irradiation (50 Gy in 25 fractions) followed by a tumor bed boost (10 Gy in 5 fractions). This easy-to-deliver PBI approach showed excellent long-term disease control with favorable safety and cosmetic outcome profiles. A plateau has been probably reached concerning the reduction of the number of fractions in the postoperative PBI setting. A 5-fraction schedule is the standard regimen and probably the appropriate compromise in terms of efficacy, safety, and quality of life, also considering the negative results of most intraoperative single-fraction PBI trials. A new frontier is now open on the potential benefit of preoperative PBI delivery, although concerns remain on the optimal dose, fractionation, and technique. Hereby we report the accelerated PBI Florence phase 3 trial experience and future perspectives.
AB - Accelerated partial breast irradiation Florence phase 3 trial is a single-center study comparing intensity-modulated based accelerated partial breast irradiation (PBI, 30 Gy in 5 fractions) and whole breast irradiation (50 Gy in 25 fractions) followed by a tumor bed boost (10 Gy in 5 fractions). This easy-to-deliver PBI approach showed excellent long-term disease control with favorable safety and cosmetic outcome profiles. A plateau has been probably reached concerning the reduction of the number of fractions in the postoperative PBI setting. A 5-fraction schedule is the standard regimen and probably the appropriate compromise in terms of efficacy, safety, and quality of life, also considering the negative results of most intraoperative single-fraction PBI trials. A new frontier is now open on the potential benefit of preoperative PBI delivery, although concerns remain on the optimal dose, fractionation, and technique. Hereby we report the accelerated PBI Florence phase 3 trial experience and future perspectives.
KW - breast cancer
KW - Florence trial
KW - intensity-modulated radiotherapy
KW - partial breast irradiation
KW - phase 3
UR - http://www.scopus.com/inward/record.url?scp=85144636850&partnerID=8YFLogxK
U2 - 10.1097/COC.0000000000000968
DO - 10.1097/COC.0000000000000968
M3 - Article
C2 - 36472353
AN - SCOPUS:85144636850
SN - 0277-3732
VL - 46
SP - 10
EP - 15
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 1
ER -
